Keryx Biopharmaceuticals Inc. - KERX- Profile

Keryx Biopharmaceuticals, Inc.. The Group's principal activities are to acquire, develop and market novel pharmaceutical products for the treatment of life-threatening diseases including diabetes and cancer. It has a product candidate SulonexT82 (Sulodexide) is a novel oral heparinoid compound for the treatment of diabetic nephropathy, a kidney disease caused by diabetes. The Group's other product candidate ZerenexT82 is currently in phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease. Additionally, the Group is developing three clinical stage oncology compounds and one neurology compound namely: KRX-0401, KRX-0402, KRX-0404 and KRX-501. It also has an active in-licensing and acquisition program designed to identify and acquire clinical-stage drug candidates. Acquires, develops and markets novel pharmaceutical products for the treatment of life-threatening diseases